HRs for overall survival from network meta-analysis
| Intervention | HR relative to dacarbazine (Network meta-analysis) | SUCRA | Quality of evidence from the network meta-analysis |
| Nivolumab | 0.45 (0.30 to 0.71) | 0.85 | Moderate |
| Pembrolizumab | 0.46 (0.26 to 0.99) | 0.81 | Very low |
| Nivolumab+ipilimumab | 0.48 (0.28 to 0.90) | 0.78 | Low |
| Vemurafenib+cobimetinib | 0.50 (0.26 to 0.96) | 0.73 | Moderate |
| Dabrafenib+trametinib | 0.55 (0.37 to 0.84) | 0.68 | Low |
| Ipilimumab+dacarbazine | 0.70 (0.47 to 0.99) | 0.41 | High |
| Ipilimumab | 0.69 (0.44 to 1.26) | 0.40 | Very low |
| Ipilimumab+gp100 | 0.72 (0.40 to 1.55) | 0.36 | Very low |
| Dabrafenib | 0.73 (0.49 to 1.10) | 0.35 | Moderate |
| Trametinib | 0.78 (0.49 to 1.22) | 0.30 | Low |
| Vemurafenib | 0.77 (0.54 to 1.10) | 0.29 | Moderate |
| Dacarbazine | 1 | 0.05 | – |
SUCRA, surface under the cumulative ranking curve.